Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics of OROS Hydromorphone in
healthy adult Taiwanese participants after oral administration of 4 different dose strengths
of 8, 16, 32 and 64 mg under fasted conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.